Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years symbols : VNDA save search
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Published: 2024-04-17 (Crawled : 13:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 35.5%
H: 4.61%
C: -3.32%
unsolicited pharmaceuticals
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
MC | $51.65 1.33% 0.0% 590K
|
Finance
|
| O: 0.56%
H: 0.8%
C: -0.41%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 35.5%
H: 4.61%
C: -3.32%
pharmaceuticals acquire for proposal
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -2.43%
H: 0.0%
C: -2.74%
fanapt fda approval treatment
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: -4.4%
hetlioz fda update treatment pharmaceuticals
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-07 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -2.28%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 0.27%
H: 20.82%
C: 11.51%
year pharmaceuticals financial results
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Published: 2024-01-31 (Crawled : 14:30) - biospace.com/
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 1.37%
H: 1.35%
C: -2.7%
vtr-297 fda drug candidate approval treatment pharmaceuticals antifungal
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 0.0%
H: 0.26%
C: -3.95%
fda resolve
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Published: 2024-01-26 (Crawled : 04:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 0.79%
H: 1.05%
C: -1.83%
ponvory patent pharmaceuticals
Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.0%
H: 0.84%
C: 0.04%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.72%
H: 0.53%
C: 0.53%
publication pharmaceuticals trial diabetic
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.11%
H: 1.03%
C: -4.13%
vca-894 fda drug candidate approval treatment pharmaceuticals
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
Published: 2024-01-19 (Crawled : 21:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
| Email alert
Add to watchlist
drug food
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
Published: 2024-01-17 (Crawled : 21:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 0.27%
H: 1.19%
C: -2.12%
publication pharmaceuticals study
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
Published: 2024-01-12 (Crawled : 22:00) - biospace.com/
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 0.77%
H: 1.27%
C: -2.53%
health care pharmaceuticals communication
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
Published: 2023-12-07 (Crawled : 12:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.61%
H: 0.0%
C: 0.0%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 6.68%
H: 1.39%
C: -7.89%
ponvory approved sclerosis pharmaceuticals
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.08%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth - Technavio
Published: 2023-11-27 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -4.49%
H: 6.23%
C: 3.42%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.21%
C: -1.93%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.28%
C: 0.21%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -3.01%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
america therapeutics growth market
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
Published: 2023-11-09 (Crawled : 23:00) - biospace.com/
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -3.46%
H: 1.91%
C: -19.14%
pharmaceuticals
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
Published: 2023-11-01 (Crawled : 21:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -0.23%
H: 2.98%
C: 2.52%
pharmaceuticals financial results
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
Published: 2023-10-20 (Crawled : 11:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -0.23%
H: 2.79%
C: 0.93%
hetlioz pharmaceuticals
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
Published: 2023-10-05 (Crawled : 23:00) - prnewswire.com
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.02%
H: 2.86%
C: 0.66%
biotech pharmaceuticals
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.